NEW YORK – Neogap Therapeutics said Tuesday that it has treated the first two colorectal cancer patients with its autologous cell therapy pTTL in a Phase I/II trial.
The pTTL therapy, which stands for personalized Tumor Trained Lymphocytes, involves engineering patients' own T cells to target tumor-specific neoantigens. The Stockholm-based company uses a technology called PIOR to select these neoantigens, then uses another technology called EpiTCer to multiply T cells so they recognize these neoantigens and attack the cancer.
The firm is conducting the Phase I/II clinical trial at Karolinska University Hospital, Danderyd's Hospital, and Västmanland Hospital in Sweden. The goal is to evaluate the pTTL treatment's safety, tolerability, and preliminary efficacy among 12 to 16 patients with stage IV colorectal cancer.
The European Union is helping fund the trial through its European Innovation Council.